Recordati Rare Diseases Announces First European Launch of Isturisa® (osilodrostat)
Recordati Rare Diseases announced today the commercial availability of Isturisa® (osilodrostat). Over 50 patients with Cushing’s syndrome have already been initiated on Isturisa® under temporary authorization for use (ATU), granted by the French National Agency for Medicines and Health Products Safety (ANSM), a special access scheme.
Isturisa®, indicated for the treatment of adult patients with endogenous Cushing’s syndrome (CS), is now available in France as the first EU country to launch. Isturisa®was granted marketing authorization by the European Commission (EC) on 9thJanuary 2020.
“Isturisa® is a meaningful addition to the treatment options for Cushing's syndrome and helps address the unmet need of patients affected by this rare and debilitating disease,” said Jacques Young, MD, PhD, Professor of Medicine at University Paris Saclay. “It is supported by data generated through prospective clinical trials within the development program of Isturisa®, providing robust evidence in terms of helping patients to achieve normal cortisol levels while also improving clinical signs and symptoms and their quality of life. Isturisa® is a new medication in our strategy of helping patients to manage Cushing's syndrome, and may be crucial for mitigating the risk of comorbidities associated with hypercortisolism.”
The European Commission approval was based on data from the development program including the pivotal LINC-3 study, which met its primary endpoint by demonstrating that a significantly higher proportion of patients continued being treated with Isturisa®, maintained normal mean urinary free cortisol (mUFC) at the end of the 8-week randomized withdrawal period (week 34) compared with the ones switched to placebo (86% vs 29%). Adverse drug reactions associated with Isturisa® and occurring in more than 20% of patients included adrenal insufficiency, fatigue, nausea, headache and edema. There were no unexpected adverse events. Isturisa® will be made available in 1-, 5- and 10-mg tablet strengths, thus allowing clinicians great flexibility for individualizing patient dosing1.
Professor Young further notes “we had the opportunity to benefit from Isturisa® as part of a special access scheme in France since April 2019. Response to the treatment has been extremely positive across the severity spectrum of Cushing’s patients, even more so when I consider my patients that have switched from current treatment options.”
The launch of Isturisa® is an addition to the Recordati Rare Diseases endocrinology portfolio which also includes Signifor®, subcutaneous and intramuscular formulations, available across Europe, indicated for the treatment of adult patients with Cushing’s disease for whom surgery is not an option or for whom surgery has failed, and for adult patients with acromegaly for whom surgery is not an option or has not been curative and who are inadequately controlled on treatment with another somatostatin analogue2.
About Cushing’s Syndrome
Cushing's syndrome (CS) is caused by an inappropriate and chronic exposure to excessive levels of cortisol. The source of this excess of cortisol can be endogenous or exogenous (ie medication). When the excess cortisol production is triggered by a pituitary adenoma (ie a tumor of the pituitary gland located in the brain) secreting excess adrenocorticotropic hormone (ACTH), the condition of the patient is defined as Cushing’s disease and is about 70% of CS cases3. It is a rare but serious disease that affects approximately one to two patients per million per year2. Cushing's disease most commonly affects adults as young as 20 to 50 years old and affects women three times more often than men4. It may present with weight gain, central obesity, a round, red full face, severe fatigue and weakness, striae (purple stretch marks), high blood pressure, depression and anxiety2. Cushing's disease can cause severe illness and death with mortality up to four times higher than in the healthy population5.
Isturisa® is a potent inhibitor of 11β-hydroxylase (CYP11B1), the enzyme responsible for the final step of cortisol synthesis in the adrenal gland. Isturisa® will be available as 1-mg, 5-mg and 10-mg film-coated tablets. Please see prescribing information for detailed recommendations for the use of this product.
Recordati, established in 1926, is an international pharmaceutical group, listed on the Italian Stock Exchange (Reuters RECI.MI, Bloomberg REC IM, ISIN IT 0003828271), with a total staff of more than 4,300, dedicated to the research, development, manufacturing and marketing of pharmaceuticals. Headquartered in Milan, Italy, Recordati has operations throughout the whole of Europe, including Russia, Turkey, North Africa, the United States of America, Canada, Mexico, some South American countries, Japan and Australia. An efficient field force of medical representatives promotes a wide range of innovative pharmaceuticals, both proprietary and under license, in a number of therapeutic areas including a specialized business dedicated to treatments for rare diseases. Recordati is a partner of choice for new product licenses for its territories. Recordati is committed to the research and development of new specialties with a focus on treatments for rare diseases. Consolidated revenue for 2019 was € 1,481.8 million, operating income was € 465.3 million and net income was € 368.9 million.
1. Isturisa® Summary of Product Characteristics. May 2020.
2. Signifor® and Signifor® LAR Summary of Product Characteristics, May 2020.
3. Nieman LK et al. Am J Med 2005;118:1340
4. Sharma ST et al. Clin Epidemiol 2015;7:281
5. Gravesen D et al. Eur J Int Med 2012;23:278
Gordon J Daniels
Head of International Marketing
Telephone: +33 (0)607531337
About Business Wire
Subscribe to releases from Business Wire
Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.
Latest releases from Business Wire
rf IDEAS ® Adds HID ® Mobile Access to Its WAVE ID ® Mobile Offering6.7.2020 22:57:00 CEST | Press release
rf IDEAS, a leading manufacturer of credential readers for logical access and authentication, continues to advance the future of secure mobile access. Developed in partnership with HID Global, the newest addition to the rf IDEAS WAVE ID Mobile reader line supports the HID Mobile Access credential on Bluetooth® Low Energy enabled mobile devices. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20200706005578/en/ WAVE ID® Mobile for HID® Mobile Access (Graphic: Business Wire) The WAVE ID Mobile for HID Mobile Access provides smartphone users with contactless logical access to workstations, networks, applications, secure printers and more via the HID credential. This new reader also provides support for nearly any physical proximity or contactless smart card in use worldwide. The HID Mobile Access credential can be obtained from HID Global through rf IDEAS. It is based on the highly secure SEOS® platform and delivered through an ea
New UC Berkeley Global Program for Freshmen Offers an Online “Study-Abroad” Option6.7.2020 19:40:00 CEST | Press release
UC Berkeley Global is proud to announce its Global Program for Freshmen (GPF), launching Fall 2020. This unique “online study-abroad” program is designed for incoming first-year university students seeking a close-knit, collaborative learning community within a digital-learning environment. Students will have access to Berkeley instructors and mentors while working closely with their peers in small cohorts using online tools. GPF offers courses in Letters & Science (L&S) that cover key prerequisites for majors across various disciplines. Elective courses allow students to complete a total of 15 credits per semester, while additional programming will focus on important issues for first-year students, including preparing for college life, selecting a major and career development. Upon completion, students earn credits that they can transfer to their home institution. This makes GPF an ideal opportunity for universities seeking a high-quality online option for their incoming students, or
Research Enhances Understanding of the Nutritional and Economic Differences in Soybean Meal from Different Origins6.7.2020 16:17:00 CEST | Press release
A new meta-analytical study reinforces U.S. Soy’s reputation for being a global leader in quality and nutrient-density. The study, entitled, “Chemical composition, protein quality and nutritive value of commercial soybean meals produced from beans from different countries,” demonstrates that not all soybean meals are created equal and that meal from different countries of origin should be treated individually when formulating swine and poultry diets. The data from this study were then processed by the Nutrient Value Calculator (NVC), a software tool constructed by Genesis Feed Technologies, a company built to bring visibility into feed costs. This cost analysis supported the economic benefits of U.S. soybean meal relative to meal from other origins as a key ingredient in poultry rations. Dr. Gonzalo Mateos, Professor of Animal Science at the University of Madrid in Spain and study co-author, first presented findings from the meta-analysis at the U.S. Soybean Export Council’s (USSEC) As
Echosens Announces NICE, UK Health Technology Assessment Organization, Issues MedTech Innovation Briefing on FibroScan Liver Exam in Primary Care6.7.2020 15:00:00 CEST | Press release
Echosens, a high-technology company offering the FibroScan family of products, announces today that the National Institute for Health and Care Excellence (NICE), the United Kingdom’s health technology assessment body providing national guidance and advice to improve health and social care, issued a MedTech Innovation Briefing (MIB) dedicated to utilization of FibroScan non-invasive technology in the primary care setting. The NICE experts concurred that this approach could provide a cost-effective way for the National Health System (NHS) to assess liver fibrosis and cirrhosis in primary care--reducing the need for treatment, referrals and biopsies, and improving accuracy and speed. “Using FibroScan as an interventional therapy helps primary care physicians and nurse specialists engage patients by demonstrating the results and outcomes as a value change that patients can visualize on a regular basis and give them confidence that their efforts have an impact,” says Louise Campbell, patien
WEP Clinical Partners With Nabriva Therapeutics for the Named Patient Supply of XENLETA ® (lefamulin)6.7.2020 13:00:00 CEST | Press release
WEP Clinical (WEP), a specialist pharmaceutical services company, has signed an exclusive agreement with Nabriva Therapeutics (Nabriva) to supply XENLETA® (lefamulin) on a named patient or expanded access basis. The Named Patient Program (NPP) is designed to ensure that physicians, contingent on meeting the necessary eligibility criteria and receiving approval, can request IV or oral XENLETA on behalf of patients who live in certain countries where it is not yet available. XENLETA was discovered and developed by Nabriva (NASDAQ: NBRV), a commercial-stage biopharmaceutical company focused on commercialization and development of anti-infective agents. It is approved by the U.S. Food and Drug Administration (FDA) for the treatment of adults with community-acquired bacterial pneumonia (CABP) caused by susceptible microorganisms. XENLETA is the first and only oral and IV pleuromutilin empiric antibiotic that acts against the pathogens that commonly cause CABP. Nabriva announced on May 29th
Pudu Robotics Raised over $15M Series B Financing with Meituan as the Exclusive Investor6.7.2020 11:11:00 CEST | Press release
On July 1, 2020, Pudu Robotics, an indoor delivery robot provider, officially announced the completion of B round financing of more than $15M with Meituan as the exclusive investor. Zhang Tao, CEO of Pudu Robotics, said the fund would be mainly used to develop products, expand sales, explore new usage scenarios and expand overseas market. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20200706005180/en/ (Photo: Business Wire) Pudu Robotics is a top-notch intelligent indoor delivery robot provider in China. The company focuses on the R&D, design and production of robots and offers a number of popular delivery robots, including PuduBot (food delivery robot), BellaBot (food delivery robot), HoloBot (building delivery robot), HolaBot (dish-return robot), and GazeBot (multi-scene delivery robot). Its first mass-produced robot PuduBot has been widely used in extensive scenarios, including restaurants, hotels, office buildings, hospi
In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.Visit our pressroom